Lebrikizumab is effective in treating head and neck atopic dermatitis and erythema at 16 weeks of treatment.

Skin cancer risk may be associated with higher levels of serum 25(OH)D.

Patients with more severe chronic hand eczema were willing to dedicate a substantial amount of time daily for treatment

Treating PsO with adalimumab and concomitant methotrexate has no difference in effectiveness and persistence when compared to adalimumab monotherapy.

PsO patients with low BSA involvement may experience similar QoL and disease burden as patients with high BSA.

Researchers have identified specific risk factors for anxiety and depression in AD patients.

Guselkumab is effective in treating moderate-to-severe scalp psoriasis in patients with Fitzpatrick Skin Types IV through VI.

Patients with GPP have a five times higher risk of all-cause mortality at one year than those without GPP.